Alzheimer’s Disease Panel
Helping Your Research
Easily assess and monitor primary molecular characteristics of Alzheimer’s disease (AD) with standardized genes covering clinically-derived AD-associated modules. Now AD expression studies can be more reproducible and translationally relevant with an efficient workflow that potentially reduces the time to clinic. Reliably assay AD phenotypes and disease progression for mouse model development and human tissue screening.
- 770 genes specific for AD studies
- Comprehensive assessment of 30 AD-associated gene co-expression modules including 23 neurodegeneration pathways and processes
- Reproducible monitoring of AD progression with age
- Functional screening of potential AD therapeutics
- Customizable with up to 55 additional user-defined genes with Panel Plus option
- nCounter workflow is streamlined, user-friendly, and efficient with just 15 minutes total hands-on time
- Human Panel available off the shelf and Mouse Panel available on-demand as a Custom CodeSet
How It Works
The content included in the nCounter AD panels represent a transcriptomic fingerprint of AD-related changes that can be directly compared to studies of mouse models of disease and back to human tissue. These panels allow for:
Pathway Based Module Analysis
Gene Set Analysis
Built-in compatibility for Panel Plus and Protein analysis
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
† Annotations for 23 fundamental pathways and processes were assigned across all genes in the Mouse AD and Human AD panel allowing for an additional view of important aspects of the onset and progression of neurodegenerative disease. Pathways and processes with >60% representative gene content per module are listed above.
‡ <60% representative pathway and process gene content per module.
* Genes selected based on human-mouse gene homology, maximal coverage of AMP-AD modules, top AGORA candidate gene status (agora.ampadportal.org), representation in AMP-AD module eigengenes, and expression in mouse brain.
Idelalisib inhibits experimental proliferative vitroretinopathy.
Proliferative vitreoretinopathy (PVR) is a fibrotic eye disease that develops after rhegmatogenous retinal detachment surgery and open-globe traumatic injury. Idelalisib is a specific inhibitor of phosphoinositide 3-kinase (PI3K) δ.
Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression.
Medulloblastoma (MB) is the most common primary malignant pediatric brain cancer. We recently identified novel roles for the MEK/MAPK pathway in regulating human Sonic Hedgehog (SHH) MB tumorigenesis.
Neurovascular injury with complement activation and inflammation in COVID-19.
The underlying mechanisms by which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to acute and long-term neurological manifestations remains obscure. We aimed to characterize the neuropathological changes in patients with coronavirus disease 2019 and determine the underlying pathophysiological mechanisms.